FDA Clears New Methylphenidate Formulation for ADHD

By |2021-11-11T17:07:13-08:00June 20th, 2017|Brief Bulletins from the Field, We Know Psychiatry|

The US Food and Drug Administration (FDA) has approved a new formulation of methylphenidate for children with attention-deficit/hyperactivity disorder (ADHD). Cotempla XR-ODT (Neos Therapeutics Inc) is the first and only methylphenidate extended-release orally disintegrating tablet for the treatment of ADHD in patients aged 6 to 17 years, the company said [...]

FDA Clears Chewable Methylphenidate (QuilliChew) for ADHD

By |2015-12-14T14:33:45-08:00December 14th, 2015|MedWorks, We Know Psychiatry|

The US Food and Drug Administration (FDA) has approved a chewable tablet form of extended-release methylphenidate (QuilliChew ER, Pfizer Inc) for attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years and older, the company announced today. The chewable product will be available in tablet form in strengths of 20, 30, and [...]

Title

Go to Top